Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time

ORLEANS, ON, June 17, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce a change in the previously set time for the Corporation's Meeting, which was originally scheduled for Thursday, June 20, 2019 at 2:00 p.m. (Eastern Daylight Time).

Due to last minute impracticability reasons, the Meeting will now be held at 10:00 a.m. (Eastern Daylight Time). The date and the location remain unchanged, namely Thursday, June 20, 2019 at the offices of Stikeman Elliott LLP located at 1155, René-Lévesque Blvd. West, 41^st Floor, Montréal, Québec H3B 3V2. The record date for determining shareholders entitled to receive notice of and vote at the Meeting remains unchanged.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical multifaced corporation with its primary focus in cannabinoid-based drug discovery and development with a clinical trial program aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma's subsidiary, Tetra Natural Health, also focuses on the development and commercialization of natural health and self-care products as well as the sale of its hemp energy drinks.

For more information visit: www.tetrabiopharma.com and www.tetranaturalhealth.com 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of CAUMZ and its other drug candidates, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

SOURCE Tetra Bio-Pharma Inc

please contact Tetra Bio-Pharma Inc.: Sabino Di Paolo, Chief Financial Officer , 613-721-2919, [email protected]; For investors information, please contact: Maison Brison, Pierre Boucher, CPA, CMA, Partner, Executive Vice-President, 514-731-0000 ext. 237, [email protected]; Media Contact: energi PR, Carol Levine, APR, FCPRS, 514-288-8500 ext. 226, [email protected]